These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 15801120

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [New treatment options for HIV-infected patients].
    Wehr A.
    Dtsch Med Wochenschr; 2004 May 07; 129(19):1093. PubMed ID: 15174468
    [No Abstract] [Full Text] [Related]

  • 3. Lopinavir/ritonavir. (Kaletra).
    Res Initiat Treat Action; 2000 Dec 07; 6(4):16-8. PubMed ID: 11708169
    [No Abstract] [Full Text] [Related]

  • 4. Anti-HIV agents. Monotherapy studies--points to consider.
    TreatmentUpdate; 2008 Jan 07; 20(1):3-4. PubMed ID: 18320692
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
    Bongiovanni M, Chiesa E, Monforte Ad, Bini T.
    Dermatol Online J; 2003 Dec 07; 9(5):28. PubMed ID: 14996401
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.
    Resino S, Bellón JM, Muñoz-Fernández MA, Spanish Group of HIV Infection.
    J Antimicrob Chemother; 2006 Mar 07; 57(3):579-82. PubMed ID: 16446377
    [No Abstract] [Full Text] [Related]

  • 12. Focus on hepatitis. Low rate of liver problems seen with LPV/r.
    Carter M.
    IAPAC Mon; 2005 Oct 07; 11(10):325. PubMed ID: 16673499
    [No Abstract] [Full Text] [Related]

  • 13. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
    Dragsted UB, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J, Jayaweera DT, Rieger A, Bruun JN, Castagna A, Gazzard B, Walmsley S, Hill A, Lundgren JD, MaxCmin2 Trial Group.
    Antivir Ther; 2005 Oct 07; 10(6):735-43. PubMed ID: 16218173
    [Abstract] [Full Text] [Related]

  • 14. Kaletra OK'd by FDA.
    James JS.
    Posit Living; 2000 Nov 07; 9(9):8, 13. PubMed ID: 12154764
    [No Abstract] [Full Text] [Related]

  • 15. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
    MMW Fortschr Med; 2003 Dec 11; 145(50):61. PubMed ID: 14963981
    [No Abstract] [Full Text] [Related]

  • 16. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E, Azuaje C, Lopez RM, Diaz M, Feijoo M, Pou L, Crespo M, Curran A, Ocaña I, Pahissa A.
    AIDS; 2006 May 12; 20(8):1131-9. PubMed ID: 16691064
    [Abstract] [Full Text] [Related]

  • 17. [Ritonavir-boosted lopinavir monotherapy due to intolerance to nucleoside reverse transcriptase inhibitors in an HIV-infected paediatric patient].
    Espiau M, Soler-Palacín P, Borrull A, Figueras C.
    Enferm Infecc Microbiol Clin; 2011 Apr 12; 29(4):319. PubMed ID: 21334110
    [No Abstract] [Full Text] [Related]

  • 18. [After 3 years no resistance development. Protease inhibitor with staying power].
    MMW Fortschr Med; 2002 Apr 09; 144 Suppl 1():56-7. PubMed ID: 12043076
    [No Abstract] [Full Text] [Related]

  • 19. A king in the CASTLE? Optimum initial HIV protease inhibitor.
    Torti C, Frank I.
    Lancet; 2008 Aug 23; 372(9639):604-6. PubMed ID: 18722849
    [No Abstract] [Full Text] [Related]

  • 20. Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra).
    TreatmentUpdate; 2008 Jan 23; 20(1):1-2. PubMed ID: 18320690
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.